Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

371 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Validation of a clinical breast cancer risk assessment tool combining a polygenic score for all ancestries with traditional risk factors.
Mabey B, Hughes E, Kucera M, Simmons T, Hullinger B, Pederson HJ, Yehia L, Eng C, Garber J, Gary M, Gordon O, Klemp JR, Mukherjee S, Vijai J, Offit K, Olopade OI, Pruthi S, Kurian A, Robson ME, Whitworth PW, Pal T, Ratzel S, Wagner S, Lanchbury JS, Taber KJ, Slavin TP, Gutin A. Mabey B, et al. Among authors: simmons t. Genet Med. 2024 Jul;26(7):101128. doi: 10.1016/j.gim.2024.101128. Epub 2024 Jun 3. Genet Med. 2024. PMID: 38829299 Free article.
Development and Validation of a Breast Cancer Polygenic Risk Score on the Basis of Genetic Ancestry Composition.
Hughes E, Wagner S, Pruss D, Bernhisel R, Probst B, Abkevich V, Simmons T, Hullinger B, Judkins T, Rosenthal E, Roa B, Domchek SM, Eng C, Garber J, Gary M, Klemp J, Mukherjee S, Offit K, Olopade OI, Vijai J, Weitzel JN, Whitworth P, Yehia L, Gordon O, Pederson H, Kurian A, Slavin TP, Gutin A, Lanchbury JS. Hughes E, et al. Among authors: simmons t. JCO Precis Oncol. 2022 Nov;6:e2200084. doi: 10.1200/PO.22.00084. JCO Precis Oncol. 2022. PMID: 36331239 Free PMC article.
International consensus to define outcomes for trials of chemoradiotherapy for anal cancer (CORMAC-2): defining the outcomes from the CORMAC core outcome set.
Samuel R, Knight SR, Adams R, Das P, Dorth J, Finch D, Guren MG, Hawkins MA, Moug S, Rajdev L, Sebag-Montefiore D, Renehan AG, Fish R; plus the CORMAC-2 collaborators. Samuel R, et al. EClinicalMedicine. 2024 Dec 5;78:102939. doi: 10.1016/j.eclinm.2024.102939. eCollection 2024 Dec. EClinicalMedicine. 2024. PMID: 39720423 Free PMC article. Review.
371 results